Stereospecific binding of 3H-phencyclidine in brain membranes.
R Y Hampton, F Medzihradsky, J H Woods, P J Dahlstrom
Life Sciences June 21, 1982 DOI: 10.1016/0024-3205(82)90288-0 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | In vitro receptor binding study Peer reviewed |
|---|---|
| Population | Rat and pigeon brain membranes, with rat liver membranes for comparison |
| Key points | Stereospecific 3H-PCP binding sites in rat and pigeon brain membranes were identified after polyethyleneimine treatment of filters removed non-tissue binding. Dexoxadrol displaced bound 3H-PCP far more potently than its inactive isomer levoxadrol, matching behavioral data, and the binding was abolished by heat but not freezing, absent in liver, and biphasically saturable at 60-70 nM and 300-400 nM. |
Abstract
Phencyclidine (PCP) displaceable binding of 3H-PCP to glass-fiber filters was eliminated and total binding markedly reduced by initial treatment of the discs with 0.05% polyethyleneimine. Assessed with treated filters, unlabeled PCP displaced 3H-PCP in both rat and pigeon brain membranes with an EC50 of 1 microM. Of similar high inhibitory potency were dextrorphan, levorphanol, SKF 10047 and ketamine, while morphine, naloxone and etorphine had EC50 values higher then 1 mM. Using the dissociative anesthetic dexoxadrol and its inactive isomer levoxadrol as displacing agents, stereospecific binding of 3H-PCP was obtained in rat and pigeon brain membranes. The markedly higher potency of dexoxadrol, relative to levoxadrol, in displacing bound 3H-PCP is compatible with behavioral data for these enantiomers. However, they were equipotent in displacing 3H-PCP bound to glass-fiber filters in the absence of tissue. Heat denaturation, but not freezing, abolished stereospecific binding of 3H-PCP, which was also absent in rat liver membranes. The stereospecific binding component in brain displayed biphasic saturability at 60-70 nM and 300-400 nM, respectively.
Citations in the library
Cited by 13
- Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans Archives of General Psychiatry March 1, 1994
- Psychotomimetic effects of PCP, LSD, and Ecstasy: pharmacological models of schizophrenia? Cambridge University Press eBooks February 4, 2010
- Some distorted thoughts about ketamine as a psychedelic and a novel hypothesis based on NMDA receptor-mediated synaptic plasticity. Neuropharmacology November 2018
- Ketamine and phencyclidine: the good, the bad and the unexpected. British Journal of Pharmacology September 2015
- NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology May 1996
and 8 more in the library